Osmotica Pharmaceuticals and Vertical Pharmaceuticals requested a declaratory judgment that Osmotica's OSMOLEX ER does not infringe on certain of Adamas Pharmaceuticals Inc.'s (Nasdaq: ADMS) patents. Shares of Adamas plummeted $7.38 to close at $26.39.
Declaratory judgment requested on Adamas Pharmaceuticals
February 20, 2018 at 18:50 PM EST